DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chlamydia Infections - Pipeline Review, H2 2016" drug pipelines to their offering.
This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Mentioned:
- Abera Bioscience AB
- Genocea Biosciences, Inc.
- Lead Discovery Center GmbH
- Merck & Co., Inc.
- NanoBio Corporation
- Prokarium Limited
- QureTech Bio AB
- SATT IDF Innov SAS
- Selecta Biosciences, Inc.
- SIGA Technologies, Inc.
- Statens Serum Institut
- Vault Pharma Inc.
Key Topics Covered:
- Introduction
- Chlamydia Infections Overview
- Therapeutics Development
- Pipeline Products for Chlamydia Infections - Overview
- Pipeline Products for Chlamydia Infections - Comparative Analysis
- Chlamydia Infections - Therapeutics under Development by Companies
- Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes
- Chlamydia Infections - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Chlamydia Infections - Products under Development by Companies
- Chlamydia Infections - Products under Investigation by Universities/Institutes
- Chlamydia Infections - Companies Involved in Therapeutics Development
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/6lxghc/chlamydia
